A detailed history of Ubs Group Ag transactions in Pulmonx Corp stock. As of the latest transaction made, Ubs Group Ag holds 22,635 shares of LUNG stock, worth $187,644. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,635
Previous 47,340 52.19%
Holding current value
$187,644
Previous $438,000 67.35%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$5.77 - $9.82 $142,547 - $242,603
-24,705 Reduced 52.19%
22,635 $143,000
Q1 2024

May 13, 2024

BUY
$8.71 - $14.65 $119,022 - $200,192
13,665 Added 40.58%
47,340 $438,000
Q4 2023

Feb 09, 2024

BUY
$7.89 - $13.14 $75,933 - $126,459
9,624 Added 40.01%
33,675 $429,000
Q3 2023

Nov 09, 2023

SELL
$9.88 - $14.0 $21,992 - $31,164
-2,226 Reduced 8.47%
24,051 $248,000
Q2 2023

Aug 11, 2023

SELL
$10.78 - $13.65 $16,148 - $20,447
-1,498 Reduced 5.39%
26,277 $344,000
Q1 2023

May 12, 2023

BUY
$7.49 - $12.54 $112,245 - $187,924
14,986 Added 117.18%
27,775 $310,000
Q4 2022

Feb 08, 2023

SELL
$4.92 - $17.35 $1,923 - $6,783
-391 Reduced 2.97%
12,789 $107,000
Q3 2022

Nov 10, 2022

BUY
$15.35 - $23.99 $71,914 - $112,393
4,685 Added 55.15%
13,180 $220,000
Q2 2022

Aug 10, 2022

SELL
$14.0 - $27.95 $63,532 - $126,837
-4,538 Reduced 34.82%
8,495 $125,000
Q1 2022

May 16, 2022

SELL
$21.13 - $35.65 $45,260 - $76,362
-2,142 Reduced 14.12%
13,033 $324,000
Q4 2021

Feb 14, 2022

BUY
$29.72 - $45.1 $353,519 - $536,464
11,895 Added 362.65%
15,175 $486,000
Q3 2021

Nov 15, 2021

BUY
$35.98 - $44.48 $107,939 - $133,440
3,000 Added 1071.43%
3,280 $118,000
Q2 2021

Aug 13, 2021

SELL
$37.61 - $48.0 $159,992 - $204,192
-4,254 Reduced 93.82%
280 $12,000
Q1 2021

May 12, 2021

BUY
$44.0 - $67.54 $108,020 - $165,810
2,455 Added 118.09%
4,534 $207,000
Q4 2020

Feb 11, 2021

BUY
$39.31 - $69.02 $81,725 - $143,492
2,079 New
2,079 $143,000

Others Institutions Holding LUNG

About Pulmonx Corp


  • Ticker LUNG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 37,268,400
  • Market Cap $309M
  • Description
  • Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...
More about LUNG
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.